[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631713":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":36,"centralContacts":37,"locations":36,"responsibleParty":43,"collaborators":36,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":36,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":36,"enrollmentInfo":54,"targetDuration":36,"studyType":57,"phases":58,"briefSummary":61,"conditions":62,"keywords":68,"overallStatus":72,"whyStopped":36,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":36},{"fullName":5,"class":6},"Recurv Pharma Inc","INDUSTRY",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"12mg of RP-001","EXPERIMENTAL","The study will begin with 12mg of RP-001.",[13],"Drug: RP-001",{"label":15,"type":10,"description":16,"interventionNames":17},"25mg of RP-001","Dose level 2 will be 25mg as determined by safety.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"75mg of RP-001","Dose level 3 will be 75mg of RP-001 as determined by safety",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"150mg of RP-001","Dose level 4 will be 150mg of RP-001 as determined by safety.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"250mg of RP-001","Dose level 5 will be 250mg as determined by safety.",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","RP-001","A new class of Taxane.",[9,23,27,15,19],null,[38],{"name":39,"role":40,"phone":41,"phoneExt":36,"email":42},"Jennifer W Curry, PharmD","CONTACT","+1-317-726-9118","jennifer.curry@recurvpharma.com",{"type":44,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100631713","phase-1-phase-12a-study-of-rp-001-in-participants-with-advanced-malignancies-100631713",false,"NCT07504263","Phase 1\u002F2a Study of RP-001 in Participants With Advanced Malignancies","An Open-label, Multicenter, Phase 1\u002F2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants With Advanced Malignancies","Inclusion Criteria:\n\n* Male or female participants aged 18 years or older with advanced or metastatic cancer, which must be measurable per RECIST v1.1 and satisfy the following criteria:\n\n  * Phase 1: Participants with solid tumors who are candidates for treatment with a taxane\n  * Phase 2a: Participants with relapsed or refractory PDAC, or CRC.\n\nExclusion Criteria:\n\n* 1\\. Active infection requiring systemic anti-infective therapy within 28 days prior to first dose of RP-001.\n\n  2\\. Cardiovascular disease, including:\n\n  a. Unstable angina; b. symptomatic peripheral arterial vascular disease; c. Myocardial infarction within 6 months prior to RP-001 administration; d. New York Heart Association Class III or IV heart failure; e. Uncontrolled arrythmia; f. ECG abnormality that, in the opinion of the Investigator, increases the risks associated with participating in the trial.\n\n  3\\. Concurrent systemic anti-cancer therapy other than luteinizing hormone-releasing hormone (LH-RH) agonists.\n\n  4\\. Pregnancy, or breastfeeding. 5. Untreated central nervous system metastasis, or carcinomatous meningitis. 6. Any concurrent severe and\u002For uncontrolled medical or surgical condition which, in the opinion of the Investigator, may compromise the participant's involvement in the trial due to safety, compliance concerns or ability to evaluate response.","ALL","18 Years",{"count":55,"type":56},66,"ESTIMATED","INTERVENTIONAL",[59,60],"PHASE1","PHASE2","Phase 1\u002F2a Study of RP-001 in participants with Advanced Malignancies",[63,64,65,66,67],"Advanced Malignancies","Oncology","Colorectal Cancer","Pancreatic Cancer","Cancer",[69,70,71],"advanced malignancies","colorectal cancer","pancreatic ductal adenocarcinoma","NOT_YET_RECRUITING","2026-03-25",{"date":75,"type":76},"2026-03-31","ACTUAL",{"date":78,"type":56},"2026-04-23",{"date":80,"type":56},"2028-04-01",{"name":5,"class":6}]